AR123116A1 - COMPOSITIONS AND METHODS FOR LOWERING CD117⁺ CELLS - Google Patents
COMPOSITIONS AND METHODS FOR LOWERING CD117⁺ CELLSInfo
- Publication number
- AR123116A1 AR123116A1 ARP180103090A ARP180103090A AR123116A1 AR 123116 A1 AR123116 A1 AR 123116A1 AR P180103090 A ARP180103090 A AR P180103090A AR P180103090 A ARP180103090 A AR P180103090A AR 123116 A1 AR123116 A1 AR 123116A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- compositions
- treatment
- depleting
- methods
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención proporciona composiciones y métodos útiles para la disminución de células CD117⁺ y para el tratamiento de varias enfermedades hematopoyéticas, trastornos metabólicos, cánceres y enfermedades autoinmunitarias, entre otros. En la presente se describen los anticuerpos, los fragmentos de unión al antígeno y sus conjugados que se pueden aplicar para efectuar el tratamiento de estas afecciones, por ejemplo, mediante la disminución de una población de células CD117⁺ en un paciente, como por ejemplo un humano. Las composiciones y los métodos que se describen en la presente, se pueden utilizar para tratar un trastorno de manera directa, por ejemplo, mediante la disminución de una población de células cancerosas CD117⁺ o de células autoinmunitarias. Las composiciones y los métodos que se describen en la presente, también se pueden utilizar para preparar un paciente para el tratamiento para el trasplante de hemocitoblastos y mejorar la incorporación del injerto de los trasplantes de hemocitoblastos mediante la disminución, de forma selectiva, de los hemocitoblastos antes del procedimiento de trasplante.The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and their conjugates that can be applied to effect the treatment of these conditions, for example, by depleting a population of CD117⁺ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for example, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein may also be used to prepare a patient for treatment for stem cell transplantation and improve engraftment of stem cell transplants by selectively depleting stem cells. before the transplant procedure.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762576571P | 2017-10-24 | 2017-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123116A1 true AR123116A1 (en) | 2022-11-02 |
Family
ID=84578011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103090A AR123116A1 (en) | 2017-10-24 | 2018-10-23 | COMPOSITIONS AND METHODS FOR LOWERING CD117⁺ CELLS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR123116A1 (en) |
-
2018
- 2018-10-23 AR ARP180103090A patent/AR123116A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004140A (en) | Compositions and methods for the depletion of cd117+ cells. | |
| MX2018015684A (en) | Compositions and methods for the depletion of cd117+cells. | |
| WO2019084057A3 (en) | Compositions and methods for the depletion of cd117+ cells | |
| BR112018076263A2 (en) | compositions and methods for cell depletion | |
| CO2021006259A2 (en) | Antibody and drug conjugates (caf) with fc silencing and their uses | |
| CO2020010956A2 (en) | Compositions and methods for the treatment of cancer and immune disorders using veillonella bacteria | |
| MX2021004579A (en) | Methods for allogeneic hematopoietic stem cell transplantation. | |
| CO2020006855A2 (en) | Compositions and methods for cd2 + cell depletion | |
| MX2022011546A (en) | Compositions and methods for the depletion of cd137+ cells. | |
| CO2020006865A2 (en) | Compositions and methods for cd5 + cell depletion | |
| BR112021021165A2 (en) | Amatoxin antibody-drug conjugates and their use | |
| MX2017014245A (en) | Compositions comprising mesenchymal stem cells and uses thereof. | |
| AU2018253575A1 (en) | Natural killer cells from placenta | |
| MX2016016756A (en) | Stem cell therapy in endometrial pathologies. | |
| WO2015181831A3 (en) | A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord | |
| AR115081A1 (en) | ISOLATED FROM MICROBACTERIA AND THEIR USES | |
| CO2020007275A2 (en) | Dosage guidelines for mobilization of hematopoietic stem and progenitor cells | |
| MX2021003383A (en) | Methods for differentiating mesenchymal stem cells. | |
| CO6640222A2 (en) | Female Biological Contraceptives | |
| WO2020219748A3 (en) | Anti-cd117 antibodies and uses thereof | |
| AR123116A1 (en) | COMPOSITIONS AND METHODS FOR LOWERING CD117⁺ CELLS | |
| MX2021005245A (en) | Oligosaccharide compositions and methods of use thereof. | |
| AR120352A1 (en) | ANTI-CD45 ANTIBODIES AND THEIR CONJUGATES | |
| EA201892659A1 (en) | COMPOSITIONS AND DECISION METHODS OF CD117 + CELLS | |
| EA202090689A1 (en) | COMPOSITIONS AND METHODS OF CD117 + CELL DEPLETION |